Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a report issued on Monday morning.

Abeona Therapeutics Stock Up 1.2 %

Shares of ABEO opened at $7.64 on Monday. The company has a 50-day simple moving average of $7.27 and a 200-day simple moving average of $5.53. The company has a market capitalization of $208.99 million, a PE ratio of -2.96 and a beta of 1.49. Abeona Therapeutics has a 52-week low of $2.77 and a 52-week high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.13). On average, research analysts anticipate that Abeona Therapeutics will post -1.83 EPS for the current year.

Insider Buying and Selling at Abeona Therapeutics

In other Abeona Therapeutics news, Director Mark Alvino sold 7,084 shares of the firm’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $5.11, for a total transaction of $36,199.24. Following the completion of the transaction, the director now directly owns 62,816 shares in the company, valued at approximately $320,989.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds have recently modified their holdings of the company. Northern Trust Corp boosted its stake in shares of Abeona Therapeutics by 5.2% during the 3rd quarter. Northern Trust Corp now owns 108,647 shares of the biopharmaceutical company’s stock worth $457,000 after purchasing an additional 5,412 shares during the last quarter. State Street Corp boosted its stake in shares of Abeona Therapeutics by 18.0% during the 2nd quarter. State Street Corp now owns 51,095 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 7,800 shares during the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth about $43,000. GSA Capital Partners LLP acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth about $49,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter worth about $52,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.